Search Results - David Urech
- Showing 1 - 4 results of 4
-
1
1389 An assessment of ROR1 expression across tumor tissue and the investigation of a ROR1-targeted T cell engager as a therapeutic strategy to target ROR1 positive tumors by Daniel Snell, Niels Kirk, David Urech, Nicole Bassler, Lucia Campos Carrascosa, Pawel Chrom, Peter Lichtlen
Published in Journal for ImmunoTherapy of Cancer (2023-11-01)Article -
2
Design of antibody variable fragments with reduced reactivity to preexisting anti-drug antibodies by Maria U. Johansson, Christopher Weinert, Dietrich Alexander Reichardt, Dana Mahler, Dania Diem, Christian Hess, Diana Feusi, Simon Carnal, Julia Tietz, Noreen Giezendanner, Fabio Mario Spiga, David Urech, Stefan Warmuth
Published in mAbs (2023-12-01)Get full text
Article -
3
An engineered T-cell engager with selectivity for high mesothelin-expressing cells and activity in the presence of soluble mesothelin by Daniel Snell, Tea Gunde, Stefan Warmuth, Bithi Chatterjee, Matthias Brock, Christian Hess, Maria Johansson, Alexandre Simonin, Fabio Mario Spiga, Christopher Weinert, Niels Kirk, Nicole Bassler, Lucia Campos Carrascosa, Naomi Flückiger, Robin Heiz, Sandro Wagen, Noreen Giezendanner, Alessandra Alberti, Yasemin Yaman, Dana Mahler, Dania Diem, Peter Lichtlen, David Urech
Published in OncoImmunology (2023-12-01)Get full text
Article -
4
A Bispecific, Tetravalent Antibody Targeting Inflammatory and Pruritogenic Pathways in Atopic Dermatitis by Julia Tietz, Tea Gunde, Stefan Warmuth, Christopher Weinert, Matthias Brock, Alexandre Simonin, Christian Hess, Maria Johansson, Fabio Spiga, Simone Muntwiler, Belinda Wickihalder, Dana Mahler, Dania Diem, Julia Zeberer, Robin Heiz, Naomi Flückiger, Noriko Shiraishi, Yoshihide Miyake, Nobuaki Takahashi, Markus Fehrholz, Marta Bertolini, Peter Lichtlen, David Urech, Daniel Snell
Published in JID Innovations (2024-03-01)Get full text
Article